Skip to main content
Erschienen in: Drugs & Aging 2/2024

10.02.2024 | Review Article

Helicobacter pylori Eradication Treatment in Older Patients

verfasst von: Paulius Jonaitis, Juozas Kupcinskas, Javier P. Gisbert, Laimas Jonaitis

Erschienen in: Drugs & Aging | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Helicobacter pylori is the main etiopathogenetic factor of chronic gastritis, peptic ulcer disease and gastric cancer. The world’s population is shifting towards older people, who have the highest prevalence of H. pylori. Aging-related peculiarities could have an impact on the treatment of H. pylori and there is still a lack of research data in the older population. The aim of this review was to summarize the findings of the most recent information, publications and studies on the issues relating to H. pylori infection in older patients. H. pylori eradication offers gastrointestinal and extra gastrointestinal benefits in older patients. Based on the main guidelines, H. pylori should be eradicated independent of the patient’s age, only reconsidering cases with terminal illness and low life expectancy. Proton pump inhibitors are generally safe and well tolerated. Some antibiotics require dose adjustment only in advanced renal insufficiency and the risk of hepatotoxicity is very low. Special precautions should be taken in patients with polypharmacy and those taking aspirin or non-steroidal anti-inflammatory drugs. In older patients, H. pylori eradication treatment frequently causes only mild and short-term adverse events; however, treatment compliance is usually still very good. H. pylori treatment in older patients does not increase the risk of Clostridium difficile infection. Optimal eradication effectiveness (> 90%) is mostly achieved with bismuth- and non-bismuth-based quadruple therapies. Susceptibility-guided treatment of H. pylori can contribute to increasing the effectiveness of eradication regimens in older adults. To achieve optimal H. pylori eradication effectiveness in older patients, the same guidelines, which are applied to adults, also apply to this population: avoiding repetitive treatment prescriptions, choosing quadruple therapies, prescribing longer treatment duration and administering high-dose proton pump inhibitors twice daily.
Literatur
1.
Zurück zum Zitat Mitchell E, Walker R. Global ageing: successes, challenges and opportunities. Br J Hosp Med. 2020;81(2):1–9. Mitchell E, Walker R. Global ageing: successes, challenges and opportunities. Br J Hosp Med. 2020;81(2):1–9.
4.
Zurück zum Zitat Singh S, Bajorek B. Defining, “Elderly” in Clinical Practice Guidelines for Pharmacotherapy. Pharm Pract (Granada). 2014;12(4):489.PubMedPubMedCentral Singh S, Bajorek B. Defining, “Elderly” in Clinical Practice Guidelines for Pharmacotherapy. Pharm Pract (Granada). 2014;12(4):489.PubMedPubMedCentral
5.
Zurück zum Zitat Sieber CC. The elderly patient—who is that? Internist (Berl). 2007;48(11):1190,1192-11901194.PubMed Sieber CC. The elderly patient—who is that? Internist (Berl). 2007;48(11):1190,1192-11901194.PubMed
6.
Zurück zum Zitat Kobayashi S, Joshita S, Yamamoto C, Yanagisawa T, Miyazawa T, Miyazawa M, et al. Efficacy and safety of eradication therapy for elderly patients with Helicobacter pylori infection. Medicine (Baltimore). 2019;98(30): e16619.PubMed Kobayashi S, Joshita S, Yamamoto C, Yanagisawa T, Miyazawa T, Miyazawa M, et al. Efficacy and safety of eradication therapy for elderly patients with Helicobacter pylori infection. Medicine (Baltimore). 2019;98(30): e16619.PubMed
7.
Zurück zum Zitat Liu T. Super-aging and Social Security for the Most Elderly in China. Z Gerontol Geriatr. 2018;51(1):105–12.PubMed Liu T. Super-aging and Social Security for the Most Elderly in China. Z Gerontol Geriatr. 2018;51(1):105–12.PubMed
8.
Zurück zum Zitat Narayanan M, Reddy KM, Marsicano E. Peptic ulcer disease and Helicobacter pylori infection. Mo Med. 2018;115(3):219–24.PubMedPubMedCentral Narayanan M, Reddy KM, Marsicano E. Peptic ulcer disease and Helicobacter pylori infection. Mo Med. 2018;115(3):219–24.PubMedPubMedCentral
9.
Zurück zum Zitat Senchukova MA, Tomchuk O, Shurygina EI. Helicobacter pylori in gastric cancer: features of infection and their correlations with long-term results of treatment. World J Gastroenterol. 2021;27(37):6290–305.PubMedPubMedCentral Senchukova MA, Tomchuk O, Shurygina EI. Helicobacter pylori in gastric cancer: features of infection and their correlations with long-term results of treatment. World J Gastroenterol. 2021;27(37):6290–305.PubMedPubMedCentral
10.
Zurück zum Zitat Norwood DA, Montalvan-Sanchez E, Dominguez RL, Morgan DR. Gastric cancer: emerging trends in prevention, diagnosis, and treatment. Gastroenterol Clin N Am. 2022;51(3):501–18. Norwood DA, Montalvan-Sanchez E, Dominguez RL, Morgan DR. Gastric cancer: emerging trends in prevention, diagnosis, and treatment. Gastroenterol Clin N Am. 2022;51(3):501–18.
11.
Zurück zum Zitat Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou J-M, Schulz C, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;71:1724–62. Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou J-M, Schulz C, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;71:1724–62.
12.
Zurück zum Zitat Jamkhande PG, Gattani SG, Farhat SA. Helicobacter pylori and cardiovascular complications: a mechanism based review on role of Helicobacter pylori in cardiovascular diseases. Integr Med Res. 2016;5(4):244–9.PubMedPubMedCentral Jamkhande PG, Gattani SG, Farhat SA. Helicobacter pylori and cardiovascular complications: a mechanism based review on role of Helicobacter pylori in cardiovascular diseases. Integr Med Res. 2016;5(4):244–9.PubMedPubMedCentral
13.
Zurück zum Zitat Kountouras J, Boziki M, Polyzos SA, Katsinelos P, Gavalas E, Zeglinas C, et al. The emerging role of Helicobacter pylori-induced metabolic gastrointestinal dysmotility and neurodegeneration. Curr Mol Med. 2017;17(6):389–404.PubMed Kountouras J, Boziki M, Polyzos SA, Katsinelos P, Gavalas E, Zeglinas C, et al. The emerging role of Helicobacter pylori-induced metabolic gastrointestinal dysmotility and neurodegeneration. Curr Mol Med. 2017;17(6):389–404.PubMed
14.
15.
Zurück zum Zitat Li Y, Choi H, Leung K, Jiang F, Graham DY, Leung WK. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(6):553–64.PubMed Li Y, Choi H, Leung K, Jiang F, Graham DY, Leung WK. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(6):553–64.PubMed
16.
Zurück zum Zitat Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420–9.PubMed Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420–9.PubMed
17.
Zurück zum Zitat Jonaityte IR, Ciupkeviciene E, Jonaitis P, Kupcinskas J, Petkeviciene J, Jonaitis L. Changes in the seroprevalence of Helicobacter pylori among the Lithuanian medical students over the last 25 years and its relation to dyspeptic symptoms. Medicina. 2021;57(3):254. Jonaityte IR, Ciupkeviciene E, Jonaitis P, Kupcinskas J, Petkeviciene J, Jonaitis L. Changes in the seroprevalence of Helicobacter pylori among the Lithuanian medical students over the last 25 years and its relation to dyspeptic symptoms. Medicina. 2021;57(3):254.
18.
Zurück zum Zitat Pilotto A, Franceschi M. Helicobacter pylori infection in older people. World J Gastroenterol. 2014;20(21):6364–73.PubMedPubMedCentral Pilotto A, Franceschi M. Helicobacter pylori infection in older people. World J Gastroenterol. 2014;20(21):6364–73.PubMedPubMedCentral
19.
Zurück zum Zitat Peng C, Hu Y, Ge Z-M, Zou Q-M, Lyu N-H. Diagnosis and treatment of Helicobacter pylori infections in children and elderly populations. Chronic Dis Transl Med. 2019;5(4):243–51.PubMed Peng C, Hu Y, Ge Z-M, Zou Q-M, Lyu N-H. Diagnosis and treatment of Helicobacter pylori infections in children and elderly populations. Chronic Dis Transl Med. 2019;5(4):243–51.PubMed
20.
Zurück zum Zitat den Hoed CM, Vila AJ, Holster IL, Perez-Perez GI, Blaser MJ, de Jongste JC, et al. Helicobacter pylori and the birth cohort effect: evidence for stabilized colonization rates in childhood. Helicobacter. 2011;16(5):405–9. den Hoed CM, Vila AJ, Holster IL, Perez-Perez GI, Blaser MJ, de Jongste JC, et al. Helicobacter pylori and the birth cohort effect: evidence for stabilized colonization rates in childhood. Helicobacter. 2011;16(5):405–9.
21.
Zurück zum Zitat Kienesberger S, Perez-Perez GI, Olivares AZ, Bardhan P, Sarker SA, Hasan KZ, et al. When is Helicobacter pylori acquired in populations in developing countries? A birth-cohort study in Bangladeshi children. Gut Microbes. 2018;9(3):252–63.PubMedPubMedCentral Kienesberger S, Perez-Perez GI, Olivares AZ, Bardhan P, Sarker SA, Hasan KZ, et al. When is Helicobacter pylori acquired in populations in developing countries? A birth-cohort study in Bangladeshi children. Gut Microbes. 2018;9(3):252–63.PubMedPubMedCentral
22.
Zurück zum Zitat Gisbert JP. The recurrence of Helicobacter pylori infection: incidence and variables influencing it. A critical review. Am J Gastroenterol. 2005;100(9):2083–209.PubMed Gisbert JP. The recurrence of Helicobacter pylori infection: incidence and variables influencing it. A critical review. Am J Gastroenterol. 2005;100(9):2083–209.PubMed
23.
Zurück zum Zitat Hu Y, Wan J-H, Li X-Y, Zhu Y, Graham DY, Lu N-H. Systematic review with meta-analysis: the global recurrence rate of Helicobacter pylori. Aliment Pharmacol Ther. 2017;46(9):773–9.PubMed Hu Y, Wan J-H, Li X-Y, Zhu Y, Graham DY, Lu N-H. Systematic review with meta-analysis: the global recurrence rate of Helicobacter pylori. Aliment Pharmacol Ther. 2017;46(9):773–9.PubMed
24.
Zurück zum Zitat Xie Y, Song C, Cheng H, Xu C, Zhang Z, Wang J, et al. Long-term follow-up of Helicobacter pylori reinfection and its risk factors after initial eradication: a large-scale multicentre, prospective open cohort, observational study. Emerg Microbes Infect. 2020;9(1):548–57.PubMedPubMedCentral Xie Y, Song C, Cheng H, Xu C, Zhang Z, Wang J, et al. Long-term follow-up of Helicobacter pylori reinfection and its risk factors after initial eradication: a large-scale multicentre, prospective open cohort, observational study. Emerg Microbes Infect. 2020;9(1):548–57.PubMedPubMedCentral
25.
Zurück zum Zitat Joo Y-E, Park H-K, Myung D-S, Baik G-H, Shin J-E, Seo G-S, et al. Prevalence and Risk factors of atrophic gastritis and intestinal Metaplasia: a Nationwide Multicenter Prospective Study in Korea. Gut Liver. 2013;7(3):303–10.PubMedPubMedCentral Joo Y-E, Park H-K, Myung D-S, Baik G-H, Shin J-E, Seo G-S, et al. Prevalence and Risk factors of atrophic gastritis and intestinal Metaplasia: a Nationwide Multicenter Prospective Study in Korea. Gut Liver. 2013;7(3):303–10.PubMedPubMedCentral
26.
Zurück zum Zitat Cizginer S, Ordulu Z, Kadayifci A. Approach to Helicobacter pylori infection in geriatric population. World J Gastrointest Pharmacol Ther. 2014;5(3):139–47.PubMedPubMedCentral Cizginer S, Ordulu Z, Kadayifci A. Approach to Helicobacter pylori infection in geriatric population. World J Gastrointest Pharmacol Ther. 2014;5(3):139–47.PubMedPubMedCentral
27.
Zurück zum Zitat Huang Q, Jia X, Chu Y, Zhang X, Ye H. Helicobacter pylori infection in geriatric patients: current situation and treatment regimens. Front Med. 2021;8: 713908. Huang Q, Jia X, Chu Y, Zhang X, Ye H. Helicobacter pylori infection in geriatric patients: current situation and treatment regimens. Front Med. 2021;8: 713908.
28.
Zurück zum Zitat Jonaitis P, Nyssen OP, Saracino IM, Fiorini G, Vaira D, Pérez-Aísa Á, et al. Comparison of the management of helicobacter pylori infection between the older and younger European Populations. Sci Rep. 2023;13(1):17235.PubMedPubMedCentralADS Jonaitis P, Nyssen OP, Saracino IM, Fiorini G, Vaira D, Pérez-Aísa Á, et al. Comparison of the management of helicobacter pylori infection between the older and younger European Populations. Sci Rep. 2023;13(1):17235.PubMedPubMedCentralADS
29.
Zurück zum Zitat Ganda Mall J-P, Östlund-Lagerström L, Lindqvist CM, Algilani S, Rasoal D, Repsilber D, et al. Are self-reported gastrointestinal symptoms among older adults associated with increased intestinal permeability and psychological distress? BMC Geriatr. 2018;18(1):75.PubMedPubMedCentral Ganda Mall J-P, Östlund-Lagerström L, Lindqvist CM, Algilani S, Rasoal D, Repsilber D, et al. Are self-reported gastrointestinal symptoms among older adults associated with increased intestinal permeability and psychological distress? BMC Geriatr. 2018;18(1):75.PubMedPubMedCentral
30.
Zurück zum Zitat Pilotto A, Maggi S, Noale M, Franceschi M, Parisi G, Crepaldi G. Association of upper gastrointestinal symptoms with functional and clinical charateristics in elderly. World J Gastroenterol. 2011;17(25):3020–6.PubMedPubMedCentral Pilotto A, Maggi S, Noale M, Franceschi M, Parisi G, Crepaldi G. Association of upper gastrointestinal symptoms with functional and clinical charateristics in elderly. World J Gastroenterol. 2011;17(25):3020–6.PubMedPubMedCentral
32.
33.
Zurück zum Zitat Shruthi R, Jyothi R, Pundarikaksha HP, Nagesh GN, Tushar TJ. A study of medication compliance in geriatric patients with chronic illnesses at a tertiary care hospital. J Clin Diagnostic Res JCDR. 2016;10(12):FC40–3. Shruthi R, Jyothi R, Pundarikaksha HP, Nagesh GN, Tushar TJ. A study of medication compliance in geriatric patients with chronic illnesses at a tertiary care hospital. J Clin Diagnostic Res JCDR. 2016;10(12):FC40–3.
34.
Zurück zum Zitat Soenen S, Rayner CK, Jones KL, Horowitz M. The ageing gastrointestinal tract. Curr Opin Clin Nutr Metab Care. 2016;19(1):12–8.PubMed Soenen S, Rayner CK, Jones KL, Horowitz M. The ageing gastrointestinal tract. Curr Opin Clin Nutr Metab Care. 2016;19(1):12–8.PubMed
35.
Zurück zum Zitat Bhutto A, Morley JE. The clinical significance of gastrointestinal changes with aging. Curr Opin Clin Nutr Metab Care. 2008;11(5):651–60.PubMed Bhutto A, Morley JE. The clinical significance of gastrointestinal changes with aging. Curr Opin Clin Nutr Metab Care. 2008;11(5):651–60.PubMed
36.
Zurück zum Zitat Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto Global Consensus Report on Helicobacter pylori Gastritis. Gut. 2015;64(9):1353–67.PubMed Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto Global Consensus Report on Helicobacter pylori Gastritis. Gut. 2015;64(9):1353–67.PubMed
37.
Zurück zum Zitat Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212–39.PubMed Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212–39.PubMed
38.
Zurück zum Zitat Chitapanarux T, Kongkarnka S, Wannasai K, Sripan P. Prevalence and factors associated with atrophic gastritis and intestinal metaplasia: a multivariate, hospital-based, statistical analysis. Cancer Epidemiol. 2023;82: 102309.PubMed Chitapanarux T, Kongkarnka S, Wannasai K, Sripan P. Prevalence and factors associated with atrophic gastritis and intestinal metaplasia: a multivariate, hospital-based, statistical analysis. Cancer Epidemiol. 2023;82: 102309.PubMed
39.
Zurück zum Zitat Eriksson NK, Kärkkäinen PA, Färkkilä MA, Arkkila PET. Prevalence and distribution of gastric intestinal metaplasia and its subtypes. Dig Liver Dis. 2008;40(5):355–60.PubMed Eriksson NK, Kärkkäinen PA, Färkkilä MA, Arkkila PET. Prevalence and distribution of gastric intestinal metaplasia and its subtypes. Dig Liver Dis. 2008;40(5):355–60.PubMed
40.
Zurück zum Zitat Liu WZ, Xie Y, Lu H, Cheng H, Zeng ZR, Zhou LY, et al. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter. 2018;23(2): e12475.PubMed Liu WZ, Xie Y, Lu H, Cheng H, Zeng ZR, Zhou LY, et al. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter. 2018;23(2): e12475.PubMed
41.
Zurück zum Zitat Leung WK, Wong IOL, Cheung KS, Yeung KF, Chan EW, Wong AYS, et al. Effects of Helicobacter pylori treatment on incidence of gastric cancer in older individuals. Gastroenterology. 2018;155(1):67–75.PubMed Leung WK, Wong IOL, Cheung KS, Yeung KF, Chan EW, Wong AYS, et al. Effects of Helicobacter pylori treatment on incidence of gastric cancer in older individuals. Gastroenterology. 2018;155(1):67–75.PubMed
42.
Zurück zum Zitat Take S, Mizuno M, Ishiki K, Kusumoto C, Imada T, Hamada F, et al. Risk of gastric cancer in the second decade of follow-up after helicobacter pylori eradication. J Gastroenterol. 2020;55(3):281–8.PubMed Take S, Mizuno M, Ishiki K, Kusumoto C, Imada T, Hamada F, et al. Risk of gastric cancer in the second decade of follow-up after helicobacter pylori eradication. J Gastroenterol. 2020;55(3):281–8.PubMed
43.
Zurück zum Zitat Wu S-R, Liu Y-H, Shi Y-Q. Is intestinal metaplasia the point of no return in the progression of gastric carcinogenesis? Chin Med J (Engl). 2021;134(24):2965–7.PubMed Wu S-R, Liu Y-H, Shi Y-Q. Is intestinal metaplasia the point of no return in the progression of gastric carcinogenesis? Chin Med J (Engl). 2021;134(24):2965–7.PubMed
44.
Zurück zum Zitat Hwang Y-J, Kim N, Lee HS, Lee JB, Choi YJ, Yoon H, et al. Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication—a prospective study for up to 10 years. Aliment Pharmacol Ther. 2018;47(3):380–90.PubMed Hwang Y-J, Kim N, Lee HS, Lee JB, Choi YJ, Yoon H, et al. Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication—a prospective study for up to 10 years. Aliment Pharmacol Ther. 2018;47(3):380–90.PubMed
45.
Zurück zum Zitat Yan L, Chen Y, Chen F, Tao T, Hu Z, Wang J, et al. Effect of Helicobacter pylori eradication on gastric cancer prevention: updated report from a randomized controlled trial with 26.5 years of follow-up. Gastroenterology. 2022;163(1):154-162.e3.PubMed Yan L, Chen Y, Chen F, Tao T, Hu Z, Wang J, et al. Effect of Helicobacter pylori eradication on gastric cancer prevention: updated report from a randomized controlled trial with 26.5 years of follow-up. Gastroenterology. 2022;163(1):154-162.e3.PubMed
46.
Zurück zum Zitat Khan MY, Aslam A, Mihali AB, Shabbir Rawala M, Dirweesh A, Khan S, et al. Effectiveness of Helicobacter pylori eradication in preventing metachronous gastric cancer and preneoplastic lesions. A systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2020;32(6):686–94.PubMed Khan MY, Aslam A, Mihali AB, Shabbir Rawala M, Dirweesh A, Khan S, et al. Effectiveness of Helicobacter pylori eradication in preventing metachronous gastric cancer and preneoplastic lesions. A systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2020;32(6):686–94.PubMed
47.
Zurück zum Zitat Chen H-N, Wang Z, Li X, Zhou Z-G. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer. 2016;19(1):166–75.PubMed Chen H-N, Wang Z, Li X, Zhou Z-G. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer. 2016;19(1):166–75.PubMed
48.
Zurück zum Zitat Ng JC, Yeomans ND. Helicobacter pylori infection and the risk of upper gastrointestinal bleeding in low dose aspirin users: systematic review and meta-analysis. Med J Aust. 2018;209(7):306–11.PubMed Ng JC, Yeomans ND. Helicobacter pylori infection and the risk of upper gastrointestinal bleeding in low dose aspirin users: systematic review and meta-analysis. Med J Aust. 2018;209(7):306–11.PubMed
49.
Zurück zum Zitat Hawkey C, Avery A, Coupland CAC, Crooks C, Dumbleton J, Hobbs FDR, et al. Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2022;400(10363):1597–606.PubMed Hawkey C, Avery A, Coupland CAC, Crooks C, Dumbleton J, Hobbs FDR, et al. Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2022;400(10363):1597–606.PubMed
50.
Zurück zum Zitat Hellström PM, Benno P, Malfertheiner P. Gastrointestinal bleeding in patients with helicobacter pylori and dual platelet inhibition after myocardial infarction. Lancet Gastroenterol Hepatol. 2021;6(9):684–5.PubMed Hellström PM, Benno P, Malfertheiner P. Gastrointestinal bleeding in patients with helicobacter pylori and dual platelet inhibition after myocardial infarction. Lancet Gastroenterol Hepatol. 2021;6(9):684–5.PubMed
51.
Zurück zum Zitat Waluga M, Kukla M, Żorniak M, Bacik A, Kotulski R. From the stomach to other organs: Helicobacter pylori and the liver. World J Hepatol. 2015;7(18):2136–46.PubMedPubMedCentral Waluga M, Kukla M, Żorniak M, Bacik A, Kotulski R. From the stomach to other organs: Helicobacter pylori and the liver. World J Hepatol. 2015;7(18):2136–46.PubMedPubMedCentral
52.
Zurück zum Zitat Yu Y-Y, Tong Y-L, Wu L-Y, Yu X-Y. Helicobacter pylori infection eradication for nonalcoholic fatty liver disease: a randomized controlled trial. Sci Rep. 2022;12(1):19530.PubMedPubMedCentralADS Yu Y-Y, Tong Y-L, Wu L-Y, Yu X-Y. Helicobacter pylori infection eradication for nonalcoholic fatty liver disease: a randomized controlled trial. Sci Rep. 2022;12(1):19530.PubMedPubMedCentralADS
53.
Zurück zum Zitat Lolekha P, Sriphanom T, Vilaichone R-K. Helicobacter pylori eradication improves motor fluctuations in advanced Parkinson’s disease patients: a prospective cohort study (HP-PD trial). PLoS ONE. 2021;16(5): e0251042.PubMedPubMedCentral Lolekha P, Sriphanom T, Vilaichone R-K. Helicobacter pylori eradication improves motor fluctuations in advanced Parkinson’s disease patients: a prospective cohort study (HP-PD trial). PLoS ONE. 2021;16(5): e0251042.PubMedPubMedCentral
54.
Zurück zum Zitat Bugdaci MS, Zuhur SS, Sokmen M, Toksoy B, Bayraktar B, Altuntas Y. The role of Helicobacter pylori in patients with hypothyroidism in whom could not be achieved normal thyrotropin levels despite treatment with high doses of thyroxine. Helicobacter. 2011;16(2):124–30.PubMed Bugdaci MS, Zuhur SS, Sokmen M, Toksoy B, Bayraktar B, Altuntas Y. The role of Helicobacter pylori in patients with hypothyroidism in whom could not be achieved normal thyrotropin levels despite treatment with high doses of thyroxine. Helicobacter. 2011;16(2):124–30.PubMed
55.
Zurück zum Zitat Centanni M, Gargano L, Canettieri G, Viceconti N, Franchi A, Delle Fave G, et al. Thyroxine in Goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med. 2006;354(17):1787–95.PubMed Centanni M, Gargano L, Canettieri G, Viceconti N, Franchi A, Delle Fave G, et al. Thyroxine in Goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med. 2006;354(17):1787–95.PubMed
56.
Zurück zum Zitat Rahmani Y, Mohammadi S, Babanejad M, Rai A, Zalei B, Shahmohammadi A. Association of Helicobacter pylori with presence of myocardial infarction in Iran: a systematic review and meta-analysis. Ethiop J Health Sci. 2017;27(4):433–40.PubMedPubMedCentral Rahmani Y, Mohammadi S, Babanejad M, Rai A, Zalei B, Shahmohammadi A. Association of Helicobacter pylori with presence of myocardial infarction in Iran: a systematic review and meta-analysis. Ethiop J Health Sci. 2017;27(4):433–40.PubMedPubMedCentral
57.
Zurück zum Zitat Azarkar Z, Jafarnejad M, Sharifzadeh G. The relationship between Helicobacter pylori infection and myocardial infarction. Casp J Intern Med. 2011;2(2):222–5. Azarkar Z, Jafarnejad M, Sharifzadeh G. The relationship between Helicobacter pylori infection and myocardial infarction. Casp J Intern Med. 2011;2(2):222–5.
58.
Zurück zum Zitat Sharma V, Aggarwal A. Helicobacter pylori: does it add to risk of coronary artery disease. World J Cardiol. 2015;7(1):19–25.PubMedPubMedCentral Sharma V, Aggarwal A. Helicobacter pylori: does it add to risk of coronary artery disease. World J Cardiol. 2015;7(1):19–25.PubMedPubMedCentral
59.
60.
Zurück zum Zitat Kovesdy CP. Epidemiology of Chronic Kidney Disease: an Update 2022. Kidney Int Suppl. 2022;12(1):7–11. Kovesdy CP. Epidemiology of Chronic Kidney Disease: an Update 2022. Kidney Int Suppl. 2022;12(1):7–11.
61.
Zurück zum Zitat Kinoshita Y, Ishimura N, Ishihara S. Advantages and disadvantages of long-term proton pump inhibitor use. J Neurogastroenterol Motil. 2018;24(2):182–96.PubMedPubMedCentral Kinoshita Y, Ishimura N, Ishihara S. Advantages and disadvantages of long-term proton pump inhibitor use. J Neurogastroenterol Motil. 2018;24(2):182–96.PubMedPubMedCentral
62.
Zurück zum Zitat Yibirin M, De Oliveira D, Valera R, Plitt AE, Lutgen S. Adverse effects associated with proton pump inhibitor use. Cureus. 2021;13(1): e12759.PubMedPubMedCentral Yibirin M, De Oliveira D, Valera R, Plitt AE, Lutgen S. Adverse effects associated with proton pump inhibitor use. Cureus. 2021;13(1): e12759.PubMedPubMedCentral
63.
Zurück zum Zitat Masclee GMC, Sturkenboom MCJM, Kuipers EJ. A benefit-risk assessment of the use of proton pump inhibitors in the elderly. Drugs Aging. 2014;31(4):263–82.PubMed Masclee GMC, Sturkenboom MCJM, Kuipers EJ. A benefit-risk assessment of the use of proton pump inhibitors in the elderly. Drugs Aging. 2014;31(4):263–82.PubMed
64.
Zurück zum Zitat Maes ML, Fixen DR, Linnebur SA. Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence. Ther Adv Drug Saf. 2017;8(9):273–97.PubMedPubMedCentral Maes ML, Fixen DR, Linnebur SA. Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence. Ther Adv Drug Saf. 2017;8(9):273–97.PubMedPubMedCentral
65.
Zurück zum Zitat Vanderhoff BT, Tahboub RM. Proton pump inhibitors: an update. Am Fam Physician. 2002;66(2):273–80.PubMed Vanderhoff BT, Tahboub RM. Proton pump inhibitors: an update. Am Fam Physician. 2002;66(2):273–80.PubMed
66.
Zurück zum Zitat Nabeta H, Shinozaki S, Abe Y, Koyanagi R, Nakamichi T, Kobayashi Y, et al. A potassium-competitive acid blocker-based regimen as second-line therapy improves Helicobacter pylori eradication. Digestion. 2020;101(3):332–8.PubMed Nabeta H, Shinozaki S, Abe Y, Koyanagi R, Nakamichi T, Kobayashi Y, et al. A potassium-competitive acid blocker-based regimen as second-line therapy improves Helicobacter pylori eradication. Digestion. 2020;101(3):332–8.PubMed
67.
Zurück zum Zitat Kiyotoki S, Nishikawa J, Sakaida I. Efficacy of vonoprazan for Helicobacter pylori eradication. Intern Med. 2020;59(2):153–61.PubMed Kiyotoki S, Nishikawa J, Sakaida I. Efficacy of vonoprazan for Helicobacter pylori eradication. Intern Med. 2020;59(2):153–61.PubMed
68.
Zurück zum Zitat Simadibrata DM, Syam AF, Lee YY. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2022;37(12):2217–28.PubMedPubMedCentral Simadibrata DM, Syam AF, Lee YY. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2022;37(12):2217–28.PubMedPubMedCentral
71.
Zurück zum Zitat Tsai C-E, Liang C-M, Lee C-H, Kuo Y-H, Wu K-L, Chiu Y-C, et al. First-line Helicobacter pylori eradication among patients with chronic liver diseases in Taiwan. Kaohsiung J Med Sci. 2016;32(8):397–402.PubMed Tsai C-E, Liang C-M, Lee C-H, Kuo Y-H, Wu K-L, Chiu Y-C, et al. First-line Helicobacter pylori eradication among patients with chronic liver diseases in Taiwan. Kaohsiung J Med Sci. 2016;32(8):397–402.PubMed
72.
Zurück zum Zitat Jung SW, Lee SW, Hyun JJ, Kim DI, Koo JS, Yim HJ, et al. Efficacy of Helicobacter pylori eradication therapy in chronic liver disease. Dig Liver Dis. 2009;41(2):134–40.PubMed Jung SW, Lee SW, Hyun JJ, Kim DI, Koo JS, Yim HJ, et al. Efficacy of Helicobacter pylori eradication therapy in chronic liver disease. Dig Liver Dis. 2009;41(2):134–40.PubMed
73.
Zurück zum Zitat Sharma NR, Wagle A, Bist M, Panthi B, Pokhrel Dahal R, Rokaya R, et al. Clarithromycin-induced Acute Liver injury in a Patient with Positive Helicobacter pylori: a Case Report and Review of the Literature. Vol. 85, Annals of medicine and surgery (2012). England; 2023. p. 4629–32. Sharma NR, Wagle A, Bist M, Panthi B, Pokhrel Dahal R, Rokaya R, et al. Clarithromycin-induced Acute Liver injury in a Patient with Positive Helicobacter pylori: a Case Report and Review of the Literature. Vol. 85, Annals of medicine and surgery (2012). England; 2023. p. 4629–32.
74.
Zurück zum Zitat Cheng D-D, He C, Ai H-H, Huang Y, Lu N-H. The possible role of Helicobacter pylori infection in non-alcoholic fatty liver disease. Front Microbiol. 2017;8:743.PubMedPubMedCentral Cheng D-D, He C, Ai H-H, Huang Y, Lu N-H. The possible role of Helicobacter pylori infection in non-alcoholic fatty liver disease. Front Microbiol. 2017;8:743.PubMedPubMedCentral
75.
Zurück zum Zitat Nyssen OP, Perez-Aisa A, Tepes B, Castro-Fernandez M, Kupcinskas J, Jonaitis L, et al. Adverse event profile during the treatment of helicobacter pylori: a real-world experience of 22,000 patients from the European registry on H. pylori management (Hp-EuReg). Am J Gastroenterol. 2021;116(6):1220–9.PubMed Nyssen OP, Perez-Aisa A, Tepes B, Castro-Fernandez M, Kupcinskas J, Jonaitis L, et al. Adverse event profile during the treatment of helicobacter pylori: a real-world experience of 22,000 patients from the European registry on H. pylori management (Hp-EuReg). Am J Gastroenterol. 2021;116(6):1220–9.PubMed
76.
Zurück zum Zitat Pulia MS, Keller SC, Crnich CJ, Jump RLP, Yoshikawa TT. Antibiotic stewardship for older adults in ambulatory care settings: addressing an unmet challenge. J Am Geriatr Soc. 2020;68(2):244–9.PubMed Pulia MS, Keller SC, Crnich CJ, Jump RLP, Yoshikawa TT. Antibiotic stewardship for older adults in ambulatory care settings: addressing an unmet challenge. J Am Geriatr Soc. 2020;68(2):244–9.PubMed
77.
Zurück zum Zitat Faulkner CM, Cox HL, Williamson JC. Unique aspects of antimicrobial use in older adults. Clin Infect Dis. 2005;40(7):997–1004.PubMed Faulkner CM, Cox HL, Williamson JC. Unique aspects of antimicrobial use in older adults. Clin Infect Dis. 2005;40(7):997–1004.PubMed
78.
Zurück zum Zitat Mégraud F, Graham DY, Howden CW, Trevino E, Weissfeld A, Hunt B, et al. Rates of antimicrobial resistance in helicobacter pylori isolates from clinical trial patients across the US and Europe. Am J Gastroenterol. 2023;118(2):269–75.PubMed Mégraud F, Graham DY, Howden CW, Trevino E, Weissfeld A, Hunt B, et al. Rates of antimicrobial resistance in helicobacter pylori isolates from clinical trial patients across the US and Europe. Am J Gastroenterol. 2023;118(2):269–75.PubMed
79.
Zurück zum Zitat Denkinger CM, Grant AD, Denkinger M, Gautam S, D’Agata EMC. Increased multi-drug resistance among the elderly on admission to the hospital—a 12-year surveillance study. Arch Gerontol Geriatr. 2013;56(1):227–30.PubMed Denkinger CM, Grant AD, Denkinger M, Gautam S, D’Agata EMC. Increased multi-drug resistance among the elderly on admission to the hospital—a 12-year surveillance study. Arch Gerontol Geriatr. 2013;56(1):227–30.PubMed
80.
Zurück zum Zitat Yoshikawa TT. Antimicrobial resistance and aging: beginning of the end of the antibiotic era? J Am Geriatr Soc. 2002;50(7 Suppl):S226–9.PubMed Yoshikawa TT. Antimicrobial resistance and aging: beginning of the end of the antibiotic era? J Am Geriatr Soc. 2002;50(7 Suppl):S226–9.PubMed
81.
Zurück zum Zitat Gao C, Fan Y-H. Effect and safety of helicobacter pylori eradication treatment based on molecular pathologic antibiotic resistance in chinese elderly people. Infect Drug Resist. 2022;15:3277–86.PubMedPubMedCentral Gao C, Fan Y-H. Effect and safety of helicobacter pylori eradication treatment based on molecular pathologic antibiotic resistance in chinese elderly people. Infect Drug Resist. 2022;15:3277–86.PubMedPubMedCentral
82.
Zurück zum Zitat Durazzo M, Ferro A, Fagoonee S, Staiano MT, Saracco GM, Pellicano R. Helicobacter pylori eradication with a clarithromycin-based triple therapy in elderly patients. Panminerva Med. 2021;63(3):332–5.PubMed Durazzo M, Ferro A, Fagoonee S, Staiano MT, Saracco GM, Pellicano R. Helicobacter pylori eradication with a clarithromycin-based triple therapy in elderly patients. Panminerva Med. 2021;63(3):332–5.PubMed
83.
Zurück zum Zitat Ma T-L, Tai W-C, Loke S-S, Yao C-C, Liang C-M, Chuah S-K. Efficacy and safety of 7-day non-Bismuth concomitant quadruple therapy for first-line Helicobacter pylori eradication in the elderly. Drugs Aging. 2023;40(1):71–9.PubMed Ma T-L, Tai W-C, Loke S-S, Yao C-C, Liang C-M, Chuah S-K. Efficacy and safety of 7-day non-Bismuth concomitant quadruple therapy for first-line Helicobacter pylori eradication in the elderly. Drugs Aging. 2023;40(1):71–9.PubMed
84.
Zurück zum Zitat Dore MP, Maragkoudakis E, Pironti A, Tadeu V, Tedde R, Realdi G, et al. Twice-a-day quadruple therapy for eradication of Helicobacter pylori in the elderly. Helicobacter. 2006;11(1):52–5.PubMed Dore MP, Maragkoudakis E, Pironti A, Tadeu V, Tedde R, Realdi G, et al. Twice-a-day quadruple therapy for eradication of Helicobacter pylori in the elderly. Helicobacter. 2006;11(1):52–5.PubMed
85.
Zurück zum Zitat Zullo A, Gatta L, De Francesco V, Hassan C, Ricci C, Bernabucci V, et al. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. Aliment Pharmacol Ther. 2005;21(12):1419–24.PubMed Zullo A, Gatta L, De Francesco V, Hassan C, Ricci C, Bernabucci V, et al. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. Aliment Pharmacol Ther. 2005;21(12):1419–24.PubMed
86.
Zurück zum Zitat Wedemeyer R-S, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37(4):201–11.PubMedPubMedCentral Wedemeyer R-S, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37(4):201–11.PubMedPubMedCentral
87.
Zurück zum Zitat Li W, Zeng S, Yu L-S, Zhou Q. Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management. Ther Clin Risk Manag. 2013;9:259–71.PubMedPubMedCentral Li W, Zeng S, Yu L-S, Zhou Q. Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management. Ther Clin Risk Manag. 2013;9:259–71.PubMedPubMedCentral
88.
Zurück zum Zitat Cadiou G, Adam M, Caussin M, Landrin I, Mariette N, Capet C, et al. Antiplatelet drugs in the elderly: prescriptions often inappropriate and reduced tolerance by associated diseases and drugs. Fundam Clin Pharmacol. 2012;26(2):307–13.PubMed Cadiou G, Adam M, Caussin M, Landrin I, Mariette N, Capet C, et al. Antiplatelet drugs in the elderly: prescriptions often inappropriate and reduced tolerance by associated diseases and drugs. Fundam Clin Pharmacol. 2012;26(2):307–13.PubMed
89.
Zurück zum Zitat Jonaitis P, Jonaitis L, Kupcinskas J. Role of genetic polymorphisms of cytochrome P450 2C19 in pantoprazole metabolism and pantoprazole-based Helicobacter pylori eradication regimens. Curr Drug Metab. 2020;21(11): 830–837. Jonaitis P, Jonaitis L, Kupcinskas J. Role of genetic polymorphisms of cytochrome P450 2C19 in pantoprazole metabolism and pantoprazole-based Helicobacter pylori eradication regimens. Curr Drug Metab. 2020;21(11): 830–837.
90.
Zurück zum Zitat Harmsze AM, de Boer A, Boot H, Deneer VHM, Heringa M, Mol PGM, et al. Interaction Between Clopidogrel and Proton Pump Inhibitors. Ned Tjdschrift voor Geneeskd. 2011;155(28):A2442. Harmsze AM, de Boer A, Boot H, Deneer VHM, Heringa M, Mol PGM, et al. Interaction Between Clopidogrel and Proton Pump Inhibitors. Ned Tjdschrift voor Geneeskd. 2011;155(28):A2442.
91.
Zurück zum Zitat Choi YJ, Kim N, Jang I-J, Cho J-Y, Nam RH, Park JH, et al. Pantoprazole does not reduce the antiplatelet effect of clopidogrel: a randomized controlled trial in Korea. Gut Liver. 2017;11(4):504–11.PubMedPubMedCentral Choi YJ, Kim N, Jang I-J, Cho J-Y, Nam RH, Park JH, et al. Pantoprazole does not reduce the antiplatelet effect of clopidogrel: a randomized controlled trial in Korea. Gut Liver. 2017;11(4):504–11.PubMedPubMedCentral
92.
Zurück zum Zitat Scott SA, Owusu Obeng A, Hulot J-S. Antiplatelet drug interactions with proton pump inhibitors. Expert Opin Drug Metab Toxicol. 2014;10(2):175–89.PubMed Scott SA, Owusu Obeng A, Hulot J-S. Antiplatelet drug interactions with proton pump inhibitors. Expert Opin Drug Metab Toxicol. 2014;10(2):175–89.PubMed
93.
Zurück zum Zitat Hines LE, Murphy JE. Potentially Harmful Drug-drug Interactions in the Elderly: a Review. Am J Geriatr Pharmacother. 2011;9(6):364–77.PubMed Hines LE, Murphy JE. Potentially Harmful Drug-drug Interactions in the Elderly: a Review. Am J Geriatr Pharmacother. 2011;9(6):364–77.PubMed
94.
Zurück zum Zitat Soraci L, Cherubini A, Paoletti L, Filippelli G, Luciani F, Laganà P, et al. Safety and tolerability of antimicrobial agents in the older patient. Drugs Aging. 2023;40(6):499–526.PubMedPubMedCentral Soraci L, Cherubini A, Paoletti L, Filippelli G, Luciani F, Laganà P, et al. Safety and tolerability of antimicrobial agents in the older patient. Drugs Aging. 2023;40(6):499–526.PubMedPubMedCentral
95.
Zurück zum Zitat Lee SP, Sung I-K, Kim JH, Lee S-Y, Park HS, Shim CS. Risk factors for the presence of symptoms in peptic ulcer disease. Clin Endosc. 2017;50(6):578–84.PubMed Lee SP, Sung I-K, Kim JH, Lee S-Y, Park HS, Shim CS. Risk factors for the presence of symptoms in peptic ulcer disease. Clin Endosc. 2017;50(6):578–84.PubMed
96.
Zurück zum Zitat Shiotani A, Manabe N, Kamada T, Fujimura Y, Sakakibara T, Haruma K. Risk and preventive factors of low-dose aspirin-induced gastroduodenal injuries: a comprehensive review. J Gastroenterol Hepatol. 2012;27(Suppl 3):8–12.PubMed Shiotani A, Manabe N, Kamada T, Fujimura Y, Sakakibara T, Haruma K. Risk and preventive factors of low-dose aspirin-induced gastroduodenal injuries: a comprehensive review. J Gastroenterol Hepatol. 2012;27(Suppl 3):8–12.PubMed
97.
Zurück zum Zitat Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. Aging Dis. 2018;9(1):143–50.PubMedPubMedCentral Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. Aging Dis. 2018;9(1):143–50.PubMedPubMedCentral
98.
Zurück zum Zitat O’Brien CW, Juraschek SP, Wee CC. Prevalence of aspirin use for primary prevention of cardiovascular disease in the United States: results from the 2017 National Health Interview Survey. Ann Intern Med. 2019;171(8):596–8.PubMedPubMedCentral O’Brien CW, Juraschek SP, Wee CC. Prevalence of aspirin use for primary prevention of cardiovascular disease in the United States: results from the 2017 National Health Interview Survey. Ann Intern Med. 2019;171(8):596–8.PubMedPubMedCentral
99.
Zurück zum Zitat Pilotto A, Franceschi M, Maggi S, Addante F, Sancarlo D. Optimal management of peptic ulcer disease in the elderly. Drugs Aging. 2010;27(7):545–58.PubMed Pilotto A, Franceschi M, Maggi S, Addante F, Sancarlo D. Optimal management of peptic ulcer disease in the elderly. Drugs Aging. 2010;27(7):545–58.PubMed
100.
Zurück zum Zitat Joo MK. Helicobacter pylori eradication in drug-related peptic ulcer. Korean J Gastroenterol. 2020;76(5):227–31.PubMed Joo MK. Helicobacter pylori eradication in drug-related peptic ulcer. Korean J Gastroenterol. 2020;76(5):227–31.PubMed
102.
Zurück zum Zitat Mullish BH, Williams HR. Clostridium difficile infection and antibiotic-associated diarrhoea. Clin Med. 2018;18(3):237–41. Mullish BH, Williams HR. Clostridium difficile infection and antibiotic-associated diarrhoea. Clin Med. 2018;18(3):237–41.
103.
Zurück zum Zitat Tawam D, Baladi M, Jungsuwadee P, Earl G, Han J. The positive association between proton pump inhibitors and Clostridium difficile infection. Inov Pharm. 2021;12(1):1–7. Tawam D, Baladi M, Jungsuwadee P, Earl G, Han J. The positive association between proton pump inhibitors and Clostridium difficile infection. Inov Pharm. 2021;12(1):1–7.
104.
Zurück zum Zitat Inghammar M, Svanström H, Voldstedlund M, Melbye M, Hviid A, Mølbak K, et al. Proton-pump inhibitor use and the risk of community-associated Clostridium difficile Infection. Clin Infect Dis. 2021;72(12):e1084–9.PubMedPubMedCentral Inghammar M, Svanström H, Voldstedlund M, Melbye M, Hviid A, Mølbak K, et al. Proton-pump inhibitor use and the risk of community-associated Clostridium difficile Infection. Clin Infect Dis. 2021;72(12):e1084–9.PubMedPubMedCentral
105.
Zurück zum Zitat Kumar S, Metz DC, Kaplan DE, Goldberg DS. Treatment of Helicobacter pylori is not associated with future clostridium difficile infection. Am J Gastroenterol. 2020;115(5):716–22.PubMedPubMedCentral Kumar S, Metz DC, Kaplan DE, Goldberg DS. Treatment of Helicobacter pylori is not associated with future clostridium difficile infection. Am J Gastroenterol. 2020;115(5):716–22.PubMedPubMedCentral
106.
Zurück zum Zitat Trifan A, Girleanu I, Cojocariu C, Sfarti C, Singeap AM, Dorobat C, et al. Pseudomembranous colitis associated with a triple therapy for Helicobacter pylori eradication. World J Gastroenterol. 2013;19(42):7476–9.PubMedPubMedCentral Trifan A, Girleanu I, Cojocariu C, Sfarti C, Singeap AM, Dorobat C, et al. Pseudomembranous colitis associated with a triple therapy for Helicobacter pylori eradication. World J Gastroenterol. 2013;19(42):7476–9.PubMedPubMedCentral
108.
Zurück zum Zitat Nishida T, Tsujii Y, Okamoto A, Tomita R, Higaki Y, Osugi N, et al. A triple-drug blister-packaged drug with vonoprazan improves first-line eradication of Helicobacter pylori in elderly patients: a retrospective propensity score-matched cohort study. Digestion. 2020;101(5):608–14.PubMed Nishida T, Tsujii Y, Okamoto A, Tomita R, Higaki Y, Osugi N, et al. A triple-drug blister-packaged drug with vonoprazan improves first-line eradication of Helicobacter pylori in elderly patients: a retrospective propensity score-matched cohort study. Digestion. 2020;101(5):608–14.PubMed
109.
Zurück zum Zitat Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Vonoprazan triple and dual therapy for Helicobacter pylori infection in the united states and europe: randomized clinical trial. Gastroenterology. 2022;163(3):608–19.PubMed Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Vonoprazan triple and dual therapy for Helicobacter pylori infection in the united states and europe: randomized clinical trial. Gastroenterology. 2022;163(3):608–19.PubMed
110.
Zurück zum Zitat Yang Q, He C, Hu Y, Hong J, Zhu Z, Xie Y, et al. 14-day pantoprazole- and amoxicillin-containing high-dose dual therapy for Helicobacter pylori eradication in elderly patients: a prospective, randomized controlled trial. Front Pharmacol. 2023;14:1096103.PubMedPubMedCentral Yang Q, He C, Hu Y, Hong J, Zhu Z, Xie Y, et al. 14-day pantoprazole- and amoxicillin-containing high-dose dual therapy for Helicobacter pylori eradication in elderly patients: a prospective, randomized controlled trial. Front Pharmacol. 2023;14:1096103.PubMedPubMedCentral
111.
Zurück zum Zitat Gao W, Ye H, Deng X, Wang C, Xu Y, Li Y, et al. Rabeprazole-amoxicillin dual therapy as first-line treatment for H. pylori eradication in special patients: a retrospective, real-life study. Helicobacter. 2020;25(5): e12717.PubMedPubMedCentral Gao W, Ye H, Deng X, Wang C, Xu Y, Li Y, et al. Rabeprazole-amoxicillin dual therapy as first-line treatment for H. pylori eradication in special patients: a retrospective, real-life study. Helicobacter. 2020;25(5): e12717.PubMedPubMedCentral
112.
Zurück zum Zitat Mestrovic A, Perkovic N, Tonkic A, Sundov Z, Kumric M, Bozic J. Personalized approach in eradication of Helicobacter pylori infection. Antibiot (Basel, Switzerland). 2022;12(1):7. Mestrovic A, Perkovic N, Tonkic A, Sundov Z, Kumric M, Bozic J. Personalized approach in eradication of Helicobacter pylori infection. Antibiot (Basel, Switzerland). 2022;12(1):7.
113.
Zurück zum Zitat Smith SM, O’Morain C, McNamara D. Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance. World J Gastroenterol. 2014;20(29):9912–21.PubMedPubMedCentral Smith SM, O’Morain C, McNamara D. Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance. World J Gastroenterol. 2014;20(29):9912–21.PubMedPubMedCentral
114.
Zurück zum Zitat Nyssen OP, Espada M, Gisbert JP. Empirical vs. susceptibility-guided treatment of Helicobacter pylori infection: a systematic review and meta-analysis. Front Microbiol. 2022;13:913436.PubMedPubMedCentral Nyssen OP, Espada M, Gisbert JP. Empirical vs. susceptibility-guided treatment of Helicobacter pylori infection: a systematic review and meta-analysis. Front Microbiol. 2022;13:913436.PubMedPubMedCentral
115.
Zurück zum Zitat Kuo C-H, Lu C-Y, Shih H-Y, Liu C-J, Wu M-C, Hu H-M, et al. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol. 2014;20(43):16029–36.PubMedPubMedCentral Kuo C-H, Lu C-Y, Shih H-Y, Liu C-J, Wu M-C, Hu H-M, et al. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol. 2014;20(43):16029–36.PubMedPubMedCentral
116.
Zurück zum Zitat Morino Y, Sugimoto M, Nagata N, Niikiura R, Iwata E, Hamada M, et al. Influence of cytochrome P450 2C19 genotype on Helicobacter pylori proton pump inhibitor-amoxicillin-clarithromycin eradication therapy: a meta-analysis. Front Pharmacol. 2021;12: 759249.PubMedPubMedCentral Morino Y, Sugimoto M, Nagata N, Niikiura R, Iwata E, Hamada M, et al. Influence of cytochrome P450 2C19 genotype on Helicobacter pylori proton pump inhibitor-amoxicillin-clarithromycin eradication therapy: a meta-analysis. Front Pharmacol. 2021;12: 759249.PubMedPubMedCentral
117.
Zurück zum Zitat Mestre A, Sathiya Narayanan R, Rivas D, John J, Abdulqader MA, Khanna T, et al. Role of probiotics in the management of Helicobacter pylori. Cureus. 2022;14(6): e26463.PubMedPubMedCentral Mestre A, Sathiya Narayanan R, Rivas D, John J, Abdulqader MA, Khanna T, et al. Role of probiotics in the management of Helicobacter pylori. Cureus. 2022;14(6): e26463.PubMedPubMedCentral
Metadaten
Titel
Helicobacter pylori Eradication Treatment in Older Patients
verfasst von
Paulius Jonaitis
Juozas Kupcinskas
Javier P. Gisbert
Laimas Jonaitis
Publikationsdatum
10.02.2024
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 2/2024
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-023-01090-w

Weitere Artikel der Ausgabe 2/2024

Drugs & Aging 2/2024 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.